Targeted pill tested to control Pre-Leukemia blood disorders
NCT ID NCT06566742
Summary
This study is testing whether a pill called olutasidenib can help control certain early-stage blood disorders that have a specific genetic change (IDH1 mutation). It will involve about 15 adults with conditions like clonal cytopenia of undetermined significance (CCUS), lower-risk myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). The main goals are to see if the drug is effective and safe, and to check if it can help patients become less dependent on blood transfusions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.